My analysis and intrinsic value of TLX March 2022, page-9

The big question that I always ask myself is - has the company fundamentals gotten better than they were six months ago? And IMO the answer is YES.

Then why is it getting sold down relentlessly? I think that the recent supply/selling pressure is from the institutions getting stopped out of their entry positions from the raise at $7.70 (new big holders with butter fingers that are forced to sell at a loss as the overall market corrects)

What has likely caused it?
- Biotech ETFs worldwide have been crucified over the last few months, and the addition to the ASX200 didn't help TLX's cause in this instance (unlucky sector drag with big vaccine names being sold etc.)
- It would be likely that the market anticipated full price Illuccix sales earlier than approx. Q2 2022 (disappointed market didn't want to wait until June/July 2022) [I must admit I was disappointed too but am fine to wait].

IMO, TLX is extremely oversold, and these prices will likely be looked at by many investors in 6-12 months as a "why the f did I not buy TLX at an approx 40% discount to a 175m institution raise"?

IMO